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Despite treatment, patients still progress to end-stage
kidney failure. In this study we showed that absence of
cystinosin results in impaired galectin-3 (Gal-3) lyso-
somal degradation, leading to inflammation and the
progression of chronic kidney disease in cystinosis.
These findings open new perspectives in potential
therapeutic targets that could limit or delay kidney
degeneration in patients with cystinosis. As such, anti-
inflammatory drugs and inhibitors of Gal-3 such as
nonsteroidal antiinflammatory drugs or indomethacin
may improve the renal pathogenesis in cystinosis.Inflammation is involved in the pathogenesis of many
disorders. However, the underlying mechanisms are often
unknown. Here, we test whether cystinosin, the protein
involved in cystinosis, is a critical regulator of galectin-3, a
member of the b-galactosidase binding protein family,
during inflammation. Cystinosis is a lysosomal storage
disorder and, despite ubiquitous expression of cystinosin,
the kidney is the primary organ impacted by the disease.
Cystinosin was found to enhance lysosomal localization
and degradation of galectin-3. In Ctns–/– mice, a mouse
model of cystinosis, galectin-3 is overexpressed in the
kidney. The absence of galectin-3 in cystinotic mice
ameliorates pathologic renal function and structure and
decreases macrophage/monocyte infiltration in the kidney
of the Ctns–/– Gal3–/– mice compared to Ctns–/– mice. These
data strongly suggest that galectin-3 mediates
inflammation involved in kidney disease progression in
cystinosis. Furthermore, galectin-3 was found to interact
with the pro-inflammatory cytokine Monocyte
Chemoattractant Protein-1, which stimulates the
recruitment of monocytes/macrophages, and proved to be
significantly increased in the serum of Ctns–/– mice and also
patients with cystinosis. Thus, our findings highlight a new
role for cystinosin and galectin-3 interaction in
inflammation and provide an additional mechanistic
explanation for the kidney disease of cystinosis. This may
lead to the identification of new drug targets to delay
cystinosis progression.
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Elsevier Inc. All rights reserved.I nflammation is a normal acute response of an organism toinjury or infection,1 but chronic inflammation is associatedwith tissue damage. In the case of chronic disease, such as
diabetes, damaged tissues activate the immune system, lead-
ing to a continuous inflammatory response and, eventually,
tissue degeneration.2 Cytokines are key modulators of
inflammation and are capable of activating or resolving the
inflammation process.3 In patients with chronic kidney dis-
ease (CKD), elevated plasma concentration of cytokines
(interleukin [IL]-6 and tumor necrosis factor–a) and
inflammation markers (C-reactive protein, IL-6, hyaluronan,
and neopterin) are associated with progression to end-stage
renal disease.4 Understanding the specific mediators that
trigger inflammatory responses facilitates the discovery of
appropriate drug targets to prevent degenerative damage.
Cystinosis is an autosomal-recessive metabolic disease that
belongs to the lysosomal storage disorder family and isKidney International (2019) 96, 350–362
T Lobry et al.: Role of galectin-3 in cystinosis ba s i c re sea r chcharacterized by the accumulation of cystine within all organs.5
The gene defective in cystinosis, CTNS, encodes the lysosomal
cystine/proton co-transporter, cystinosin.6,7 Although CTNS is
ubiquitously expressed, the kidney is the first organ affected
in persons with cystinosis. Patients typically present in their
first year of life with Fanconi syndrome, characterized by severe
fluid and electrolyte disturbances, poor growth, and rickets.8
CKD subsequently develops, which progresses to end-stage
renal disease and requires kidney transplantation. Cystine
accumulation in all tissues eventually leads to multiorgan
dysfunction; patients experience photophobia and blindness,
hypothyroidism, hypogonadism, diabetes, myopathy, and cen-
tral nervous system deterioration.9 In the C57BL/6 background,
a knockout mouse model (Ctns–/–)10 replicates the kidney
phenotypeof cystinoticpatients,11 aswell as deposition of cystine
crystals in the cornea12 and thyroid dysfunction.13
Besides supportive therapy, the current treatment for cysti-
nosis is the substrate depletion drug cysteamine,whichdelays the
progression of cystinosis complications but has no effect on
Fanconi syndrome and does not prevent end-stage renal
disease.14–16 The specific sensitivity of the kidneys in persons
with cystinosis is still not fully understood because cystine ac-
cumulates in all tissues.17 Recently, new cellular pathways were
shown to be affected by the absence of cystinosin, in addition to
cystine transport. As such, chaperone-mediated autophagy
(CMA), a selective autophagy degrading KFERQ sequence-
bearing proteins, is impaired, and lysosome-associated mem-
brane protein 2, a main protagonist of CMA, is mislocalized in
murine Ctns-deficient cells and tissues.18 Interaction of cys-
tinosin with almost all components of vacuolar-type Hþ aden-
osine triphosphatase, ragulator, and RagA/RagC was
demonstrated, as well as defective lysosomal recruitment of
mammalian target of rapamycin upon nutrient re-introduction
after shortage in the absence of cystinosin.19 Expression of
transcription factor EB, a regulator of lysosomal clearance,
autophagy, and anabolism, also was shown to be impaired in
cystinosin-deficient proximal tubular cells.20 A striking common
property of these studies is that defects in mammalian target of
rapamycin signaling, transcription factor EB expression, and
CMA could not be corrected upon cystine clearance by cyste-
amine, showing that these cellular anomalies are due to the
absence of cystinosin, besides cystine overload.18–20
In the present study, we reveal a new role for cystinosin in
inflammation through its interaction with Gal-3. Gal-3 is a
member of the lectin and b-galactoside–binding protein
family 21 and is involved in multiple biologic functions,
including inflammation.22 In the context of kidney diseases,
Gal-3 inhibition was shown to reduce proinflammatory
marker expression and renal fibrosis and prevent the decline
of glomerular filtration rate in hyperaldosteronism, hyper-
tension, or obesity models.23–26 Here we provide evidence
that, in cystinosis, absence of cystinosin leads to Gal-3 over-
expression in kidneys, enhancing macrophage infiltration and
CKD progression. In addition, we identify monocyte che-
moattractant protein–1 (MCP-1) as a potential mediator,
revealing new gene targets for drug therapy.Kidney International (2019) 96, 350–362RESULTS
Gal-3 interacts with cystinosin via its carbohydrate
recognition domain
To identify specific interaction partners using quantitative
mass spectrometry, Madin-Darby canine kidney (MDCK)
cells were transduced with a lentiviral construct to stably
express the cystinosin–green fluorescent protein (GFP) fusion
protein. In addition to the 9 subunits of vacuolar-type Hþ
adenosine triphosphatase published previously,19 Gal-3 was
identified as one of the proteins interacting with cystinosin
(Figure 1a). This interaction was further confirmed by co-
immunoprecipitation followed by Western blotting
(Figure 1b and c). In addition, we showed that interaction
between Gal-3 and cystinosin was mediated by Gal-3 carbo-
hydrate recognition domain (CRD) localized in the C-ter-
minal tail of the protein. Interaction was inhibited by
thiodigalactoside, a potent inhibitor of galectin-carbohydrate
interactions (Figure 1d). Like all galectins, Gal-3 has an af-
finity for glycosylated proteins,21 so it is likely that the
interaction with Gal-3 occurs through the cystinosin glyco-
sylated moiety located in the intralysosomal N-terminal tail of
the protein.27
Cystinosin enhances Gal-3 lysosomal localization and
degradation
To verify the potential lysosomal localization of Gal-3 when
interacting with cystinosin, we showed that Gal-3, like
cathepsin D (an intralysosomal protease), was protected from
digestion by proteinase K, whereas both proteins were
digested when lysosomes were permeabilized with Triton X-
100 (Figure 2a and Supplementary Figure S1). Similar data
were obtained in lysosomes isolated from mouse liver, con-
firming lysosomal localization of Gal-3 in vivo (Figure 2b and c).
Because of the absence of reliable antibody to detect cystinosin,
immunostaining was performed on cystinosin-GFP–expressing
MDCK cell lines with an anti–Gal-3 antibody. It confirmed the
presence of Gal-3 in the lumen of the lysosomes, whereas
cystinosin-GFP and Lamp-2 (a lysosomal transmembrane pro-
tein) were found only at the membrane of the vesicles
(Figure 2d).
To investigate if cystinosin was involved in Gal-3 traf-
ficking, we analyzed the dynamics of both cystinosin and
Gal-3–positive vesicles using dual-color live cell total in-
ternal reflection fluorescence microscopy in mouse em-
bryonic fibroblasts (MEFs) from wild-type (WT) and
Ctns–/– mice expressing both CTNS-DsRed and Gal-3–GFP.
Our analysis confirmed that cystinosin and Gal-3 undergo
true colocalization in Ctns–/– MEFs as validated by the
similar spatiotemporal distribution of these molecules in
the total internal reflection fluorescence microscopy zone
(Figure 2e). Data in WT MEFs were similar (data not
shown). Moreover, when MEFs transfected only with Gal-
3–GFP were analyzed, Gal-3–GFP was found in the cyto-
plasm and no distinct vesicular structure was observed,
contrary to the co-transfection with CTNS-DsRed (data not
shown).351
Figure 1 | Galectin-3 (Gal-3) interacts with cystinosin–green fluorescent protein (GFP) via its carbohydrate recognition domain. (a)
Volcano plot representation of proteins immunoprecipitated by the anti-GFP antibody and identified by mass spectrometry (nanoRSLC-Q
Exactive Plus MS) in Madin-Darby canine kidney (MDCK) cells overexpressing cystinosin-GFP versus nontransfected cells (4 independent
experiments). Lysates of MDCK cells stably expressing cystinosin-GFP were immunoprecipitated with (b) anti-GFP or (c) anti–Gal-3 anti-
bodies, and co-immunoprecipitated proteins were analyzed by Western blotting (n ¼ 3). (d) Lysates of MDCK cells stably expressing
cystinosin-GFP were treated or not treated for 30 minutes with 5 mM thiodigalactoside (TDG), a potent inhibitor of galectin-carbohydrate
interactions. Lysates were then immunoprecipitated with anti-GFP antibodies and co-immunoprecipitated proteins were analyzed by
Western blotting (n ¼ 3). ATPase, adenosine triphosphatase; IP, immunoprecipitation. To optimize viewing of this image, please see the
online version of this article at www.kidney-international.org.
bas i c re sea r ch T Lobry et al.: Role of galectin-3 in cystinosisThese data were confirmed in 293T cells, in which a
strong GFP signal in the cytoplasm was observed in cells
expressing only Gal-3–GFP, whereas in cells expressing both
Gal-3–GFP and cystinosin-DsRed, Gal-3–GFP was mainly
localized within cystinosin-DsRed–expressing lysosomes
(Figure 3a). Moreover, quantification of Gal-3 protein
expression in cells transfected with Gal-3–GFP alone or Gal-
3–GFP and CTNS-DsRed, and Gal-3–GFP and DsRed as
control, showed significantly less Gal-3–GFP proteins in
cells co-transfected with CTNS-DsRed compared with cells
transfected with Gal-3–GFP alone or co-transfected with
DsRed (Figure 3b). Altogether, these results suggest that
cystinosin enhances the lysosomal localization and degra-
dation of Gal-3.
Cystinosin was shown to be involved in CMA.28 Heat
shock 70 kDa protein (Hsc70) participates in CMA by aiding
the unfolding and translocation of substrate proteins across
the membrane into the lysosomal lumen in a LAMP2A-
dependent manner.29,30 Because Gal-3 was proposed to be
degraded by CMA,31 we investigated the localization of Gal-3
relative to Hsc70 in cystinotic MEFs. Confocal microscopy
analysis confirmed the colocalization of Gal-3–GFP at Hsc70-
positive structures in both WT (data not shown) and Ctns–/–
cells (Figure 3c), supporting the co-transportation of Gal-3
with Hsc70 and suggesting that lysosomal internalization
but not Gal-3 recognition by the chaperone is defective in
cystinosis.352Gal-3 is involved in kidney inflammation in Ctns–/– mice
To study the role of Gal-3 in cystinosis in vivo, we generated a
double knockout mouse model deficient in both cystinosin
and Gal-3 (Ctns–/– Gal-3–/– mice). WT, Ctns–/–, and Gal-3–/–
mice were used as control subjects. In the C57BL/6 Ctns–/–
mice, renal anomalies appear around 10 months of age.11
Therefore, studies were performed at 8 to 9 months, when
kidney anomalies start to be detected, and at 12 to 15 months,
when kidney anomalies have progressed. Because cystine
content was found to be different in male and female Ctns–/–
kidneys, they were analyzed separately. If cystine content in-
creases with age in both genotypes, no significant difference
was observed in male and female kidneys between the Ctns–/–
Gal-3–/– mice and Ctns–/– mice at 8 to 9 months and 12 to 15
months of age (Figure 4a).
Renal function was assessed in serum and urine and no
significant difference was observed between WT and Ctns–/–
mice at 8 to 9 months (data not shown), but at 12 to 15
months, Ctns–/– mice showed significantly higher serum
creatinine and urea levels compared with WT mice. Inter-
estingly, Ctns–/– Gal-3–/– mice exhibited improved renal
function compared with Ctns–/– mice at 12 to 15 months,
with lower serum creatinine (P < 0.05) and urea (P < 0.05;
Table 1).
Histologic studies of 8- to 9-month-old and 12- to 15-
month-old mouse kidney sections revealed the presence of
severe anomalies in Ctns–/– kidneys, including tubularKidney International (2019) 96, 350–362
Figure 2 | Galectin-3 (Gal-3) is localized into the lumen of late endosomes and lysosomes. (a) Lysates of Madin-Darby canine kidney
(MDCK) cells stably expressing cystinosin–green fluorescent protein (GFP) were treated or not treated with 2.5 mg/ml proteinase K for 30
minutes at 4 C in the presence or absence of 2% Triton X-100 that permeabilized internal membranes. The samples were loaded on sodium
dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and processed for immunoblot with either anti-GFP (localized on the
outer aspect of the lysosome), anti–cathepsin-D (intralysosomal hydrolase), or anti–Gal-3 antibodies. (b) Lysates (Ly) or lysosome-enriched
fractions (LEF) from mouse liver were probed with the indicated antibodies. (c) Lysosome-enriched fractions were treated or not treated with
25 mg/ml proteinase K for 30 minutes at 4 C in the presence or absence of 2% Triton X-100. The samples were loaded on SDS-PAGE
and processed for immunoblot with anti–Gal-3 antibodies. (d) Immunostaining of late endosomes and lysosomes with lysosome-associated
membrane protein 2 (Lamp-2) in cystinosin-GFP MDCK cell lines revealed a co-localization between cystinosin-GFP and Lamp-2 at the
lysosomal membrane. Gal-3 is present within the vesicles, whereas cystinosin-GFP is located at the membrane of the vesicles. Bar ¼ 10 mm.
(e) Ctns–/– mouse embryonic fibroblasts expressing both Gal-3–GFP and cystinosin-DsRed were analyzed by total internal reflection fluo-
rescence microscopy. Vesicular trafficking was monitored during 60 seconds and analyzed using ImageJ software. Magnifications of the
selected areas are represented in the bottom panels and show true co-localization as determined by the spatiotemporal co-distribution of
the proteins (indicated with arrows). A total of 9 cells were analyzed for each condition. Bar ¼ 2 mm. The dynamics of the labeled vesicles
and the spatiotemporal distribution of Gal-3 and cystinosin can be viewed in associated Supplementary Movies S1 and S2. To optimize
viewing of this image, please see the online version of this article at www.kidney-international.org.
T Lobry et al.: Role of galectin-3 in cystinosis ba s i c re sea r chatrophy, retracted glomeruli, and mononuclear infiltrates.
Blind analysis of kidney sections ranged the extent of
cortical damage from 1 (preserved tissue structure) to 6.
The average score for Ctns–/– mice was 2.64  0.36 at 9
months of age (n ¼ 7) and 4.12  0.37 at 12 to 15 months
of age (n ¼ 16). In the kidneys of Ctns–/– Gal-3–/– mice at
the same age, these anomalies were significantly less
extensive: 1.62  0.11 at 9 months (n ¼ 21; P < 0.05,Kidney International (2019) 96, 350–362Mann-Whitney t test) and 3.04  0.22 at 12 to 15 months
(n ¼ 33; P < 0.05, Mann-Whitney t test) (Figure 4b and
Supplementary Figure S2). Moreover, a percentage of
tubular atrophy was assigned to every tissue, and the average
for Ctns–/– mice and Ctns–/– Gal-3–/– mice were 66% and
42%, respectively, at 12 to 15 months (P ¼ 0.01).
Furthermore, a striking difference between Ctns–/– and
Ctns–/– Gal-3–/– kidney sections was the presence of few353
Figure 3 | Cystinosin enhances Galectin-3 (Gal-3) lysosomal localization and degradation. (a) Fluorescent images of large views of 293T
cells transfected with Gal-3–green fluorescent protein (GFP) alone or with either DsRed or cystinosin-DsRed. Bar ¼ 50 mm. (b) Proteins
were isolated from the transfected 293T cells, resolved on sodium dodecylsulfate–polyacrylamide gel electrophoresis, revealed with an anti–
Gal-3 or anti–glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody as reference, and quantified using ImageJ software, n ¼ 3;
statistical test used was 1-way analysis of variance followed by Tukey’s test. *P < 0.05; **P < 0.01. (c) Ctns–/– mouse embryonic
fibroblasts were transfected with Gal-3–GFP expression vector and immunostained for endogenous Hsc70. Bar ¼ 20 mm. To optimize
viewing of this image, please see the online version of this article at www.kidney-international.org.
bas i c re sea r ch T Lobry et al.: Role of galectin-3 in cystinosismononuclear infiltrates in the Ctns–/– Gal-3–/– sections,
whereas heavy infiltrates were consistently observed in the
Ctns–/– kidney (Figure 4b).
We characterized the mononuclear infiltrates observed by
histologic examination in 8- to 9-month-old Ctns–/– kidneys
as macrophages/monocytes by co-immunostaining with354CD68 and CD45 and with CD68 and major histocompati-
bility class II (Supplementary Figure S3), but not with CD68
and CD163, suggesting that these macrophages have a M1-
like proinflammatory profile.32,33 Quantification of CD68-
positive cells revealed significantly fewer macrophages/
monocytes in WT, Gal-3–/–, and Ctns–/– Gal-3–/– kidneysKidney International (2019) 96, 350–362
Figure 4 | Effect of the absence of Galectin-3 (Gal-3) on renal function and kidney structure in 12- to 15-month-old mice. (a) Cystine
content levels (nmol half cystine/mg protein) in the kidney of male (left panel) and female (right panel) Ctns–/– and Ctns–/– Gal-3–/– mice at 8
to 9 months (Ctns–/–: n ¼ 11, 6 males and 5 females; Ctns–/– Gal-3–/–: n ¼ 21, 7 males and 14 females) and 12 to 15 months (Ctns–/–: n ¼ 16,
5 males and 11 females; Ctns–/– Gal-3–/–: n ¼ 34, 12 males and 22 females). P values were determined using the unpaired 2-tailed Student
t-test with Welch’s correction. (b) Histologic pictures of kidney sections from wild-type, Ctns–/–, Gal-3–/–, and Ctns–/– Gal-3–/– mice at 12
months of age stained with hematoxylin and eosin. Mononuclear infiltrates are indicated by arrows. (c) Kidney sections from wild-type,
Ctns–/–, and Ctns–/– Gal-3–/– mice at 8 to 9 months of age were stained with anti-CD68 antibodies (green), phalloidin (white), and 40,6-
diamidino-2-phenylindole (blue). Bar ¼ 50 mm. Quantification was then performed using ImageJ software (wild type: n ¼ 3; Ctns–/– and
Ctns–/–Gal-3–/–: n ¼ 4). P values were determined using 1-way analysis of variance followed by Tukey’s test. **P < 0.01. NS, not significant. To
optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
T Lobry et al.: Role of galectin-3 in cystinosis ba s i c re sea r chcompared with Ctns–/– kidneys (Figure 4c), confirming the
histologic data (Figure 4b).
Altogether, these findings suggest that Gal-3 is involved in
the recruitment of macrophages/monocytes in cystinotic
kidneys and that its absence ameliorates kidney disease in
Ctns–/– mice. Hence it suggests that inflammation is respon-
sible, at least in part, for kidney deterioration in Ctns–/– mice.Kidney International (2019) 96, 350–362Ctns-deficient kidneys exhibit Gal-3 overexpression
Using Western blot analysis, we found that Gal-3 expression
was significantly increased in kidneys of 12-month-old
Ctns–/– mice compared with WT mice (Figure 5a and b). To
investigate if this increased expression of Gal-3 is specific to
Ctns–/– kidneys, we quantified Gal-3 expression at the tran-
script and protein levels in kidneys from mice with CKD355
Table 1 | Serum and urine analyses for renal function of 12- to 15-month-old mice
Wild type (n [ 13) Ctns–/– (n [ 16) Gal-3–/– (n [ 5) Ctns–/– Gal-3–/– (n [ 34)
Serum
Creatinine (mg/dl) 0.29  0.02 0.41  0.03a 0.26  0.02b 0.31  0.01b
Urea (mg/dl) 48.95  3.25 90.35  3.34a 52.68  2.15b 77.43  2.49a,b,c
Phosphate (mg/dl) 13.84  1.07 12.87  1.03 12.06  0.28 12.03  0.46
Urine
Phosphate (mmol/24 h) 4.30  0.62 5.56  0.75 2.89  0.81 6.06  0.81
Protein (mg/24 h) 12.36  1.96 13.06  2.04 14.69  3.94 12.51  1.42
Volume (ml) 0.85  0.14 1.29  0.14 0.89  0.25 1.25  0.12
Gal-3, Galectin-3.
P value was calculated by 1-way analysis of variance followed by Tukey’s test.
aP < 0.05 compared with wild-type mice.
bP < 0.05 compared with Ctns–/– mice.
cP < 0.05 compared with Gal-3–/– mice.
bas i c re sea r ch T Lobry et al.: Role of galectin-3 in cystinosisinduced by standard subtotal 2-step nephrectomy operation
and from the animals that underwent a sham operation. WT
and Ctns–/– mice were used as control subjects. Gal-3 tran-
scripts were significantly increased in Ctns–/– and sham kid-
neys but highly increased in CKD kidneys compared with WT
mice (Figure 5c). In contrast, at the protein level, Gal-3 was
detected only in Ctns–/– kidneys, strongly suggesting that only
Ctns–/– kidneys were unable to degrade Gal-3 protein
(Figure 5d). Immunofluorescent staining of Gal-3 in murine
kidney at 8 to 9 months also demonstrated overexpression of
Gal-3 in the Ctns–/– kidneys compared with WT kidneys
(Figure 5e). Moreover, Gal-3 was expressed by CD68þ mac-
rophages, as well as renal cells in Ctns–/– kidneys at 8 to 9
months (Supplementary Figure S4). Altogether, these data are
consistent with decreased Gal-3 degradation in the absence of
cystinosin as demonstrated in vitro (Figure 3a and b), leading
to accumulation of Gal-3 protein in Ctns–/– kidneys.
Absence of cystinosin leads to increased serum MCP-1 via
Gal-3 upregulation
Gal-3 regulates inflammation through different mecha-
nisms.34 Thus, to gain further insights into the mechanism in
cystinosis, we investigated the expression of different proin-
flammatory or antiinflammatory cytokines in the serum of
12- to 15-month-old WT, Ctns–/–, Gal-3–/–, and Ctns–/– Gal-
3–/– mice. Six cytokine levels were measured by mouse cyto-
metric bead array, MCP-1, interferon-g, tumor necrosis
factor, and IL-10, IL-6, and IL-12p70. Only MCP-1 expression
was significantly increased in Ctns–/– mice serum compared
with WT and Gal-3–/– mice and also to Ctns–/– Gal-3–/– mice,
whose MCP-1 serum levels were comparable with WT mice
(Figure 6a). MCP-1 is produced by different cell types, with
the major source of MCP-1 being macrophages and mono-
cytes,35 and is acting as a chemoattractant for monocytes and
macrophages regulating their migration and infiltration. In
contrast, at the same age, Gal-3 expression was found to be
similar in the serum of Ctns–/– mice (44.33  9.81 ng/ml; n ¼
5) and WT mice (40.86  6.41 ng/ml; n ¼ 7).
The relationship between Gal-3 and MCP-1 was further
investigated by co-immunoprecipitation using Gal-3–GFP
and MCP-1–DsRed– or Gal-3–GFP and CTNS-DsRed– (as a
positive control) expressing 293T cells. Interaction between356Gal-3 and MCP-1 was observed (Figure 6b), suggesting a
direct induction of MCP-1 by Gal-3. Incubation with N-
Acetyl-D-lactosamine (LacNAc), an inhibitor of Gal-3 CRD,
showed that, in contrast to cystinosin interaction, the CRD is
not involved in the interaction between Gal-3 and MCP-1
(Figure 6c).
To assess whether this finding is relevant in humans, we
measured Gal-3 and MCP-1 levels in patients with cystinosis
who were not undergoing immunosuppressive therapy or
taking antiinflammatory medications. Although the Gal-3
level was found to be slightly increased in the serum of pa-
tients with cystinosis compared with healthy donors, the
difference was not significant (Figure 6e), confirming our
results obtained in Ctns–/– mice. Only 2 patients had a high
Gal-3 level (25.34 and 39.54 ng/ml); they were considered
outliers and thus were not included in Figure 6e. In contrast,
using an enzyme-linked immunosorbent assay directed
against human MCP-1 (Figure 6d), serum MCP-1 levels were
found to be significantly increased in patients with cystinosis
(252.1  18.4 pg/ml; n ¼ 19; age range 1–23 years) despite
cysteamine treatment compared with healthy control subjects
(166.9  13.5 pg/ml; n ¼ 10; age range 8–63 years) (P <
0.001). No correlation has been found between age and MCP-
1 level in both patients with cystinosis and healthy donors
(data not shown).
DISCUSSION
Despite the fact that cystine accumulates in all tissues in pa-
tients affected with cystinosis, kidneys are the organs that are
the most vulnerable to damage. Thus we believe cystine
accumulation is not solely responsible for kidney degenera-
tion. Herein, we describe a new role for cystinosin in the
regulation of inflammation involved in the progression of
chronic renal disease in cystinosis. This study may explain
why patients evolve to end-stage renal failure despite under-
going cysteamine therapy.
The study of cystinosin’s molecular partners revealed a
direct interaction with Gal-3, which can be inhibited by in-
hibitors of Gal-3 CRD. Recent studies showed that Gal-3
could interact with glycans located in the lysosomal lumen
after lysosomal damage such as crystal buildup.36 In our
study, the interaction between Gal-3 and cystinosin wasKidney International (2019) 96, 350–362
Figure 5 | Galectin-3 (Gal-3) expression is increased in the Ctns–/– mice. Gal-3 expression in whole kidney homogenates of 12-month-old
wild-type or Ctns–/– mice was evaluated by (a) Western blot and (b) quantified using ImageJ software (wild type: n ¼ 6; Ctns–/–: n ¼ 9). P
values were determined using the unpaired 2-tailed Student t-test with Welch’s correction. **P < 0.01. mRNA and proteins were isolated
from kidneys of sham-operated (n ¼ 6) or 5/6 nephrectomized (chronic kidney disease; n ¼ 6) animals, and Gal-3 expression was deter-
mined by droplet digital polymerase chain reaction (c) or Western blot (d). Protein lysates of kidney from WT and Ctns–/– mice at 12 months
were used as negative and positive controls, respectively, for Gal-3 expression. P values were determined using 1-way analysis of variance
followed by Tukey’s test. **P < 0.01. ***P < 0.0001. (e) Wild-type, Ctns–/–, and Ctns–/– Gal-3–/– kidneys were stained with anti–Gal-3
antibodies (green), phalloidin (white), and 40,6-diamidino-2-phenylindole (blue). Bar ¼ 50 mm. To optimize viewing of this image, please see
the online version of this article at www.kidney-international.org.
T Lobry et al.: Role of galectin-3 in cystinosis ba s i c re sea r chstudied in healthy cells expressing cystinosin and, therefore,
not accumulating cystine or cystine crystals. In addition,
overexpression of both Gal-3 and cystinosin in healthy cells
modified the subcellular localization of Gal-3, which was then
localized to the lysosomes, compared with overexpression of
Gal-3 only, which was located in the cytoplasm. These results
strongly suggest that interaction between Gal-3 and cystinosin
is occurring independently of lysosomal damage and that
cystinosin is actively responsible for Gal-3 lysosomal locali-
zation. Previously Gal-3 has been shown to be degraded
through lysosomal-dependent proteolysis in absence of cAbl
and Arg, 2 tyrosine kinases.31
In addition, we showed that cystinosin and Gal-3
co-localize at dynamic vesicular structures and areKidney International (2019) 96, 350–362together mobilized in a spatiotemporal manner. Cystinosin
previously has been associated with the trafficking mecha-
nisms of the lysosomal LAMP2A, the only known CMA
receptor, which is mislocalized in cystinosis.28 Gal-3
degradation previously has been shown to be mediated by
CMA.31 Confocal microscopy analysis confirmed the
colocalization of Gal-3 at Hsc70-positive structures in both
Ctns–/– and WT cells, supporting the co-transportation of
Gal-3 with Hsc70 for presentation at the lysosome and
degradation by CMA as Hsc70 aids the translocation of
substrate proteins across the membrane into the lysosomal
lumen.29,30 A possible interpretation of our results is that
cystinosin regulates the trafficking and delivery of Gal-3 to
the CMA-active lysosomes for degradation.357
Figure 6 | Galectin-3 (Gal-3) interacts with monocyte chemoattractant protein–1 (MCP-1), a macrophage/monocyte chemoattractant
protein upregulated in cystinotic mice serum. (a) A cytometric beads array has been used to determine MCP-1 concentration in the
serum of wild-type (n ¼ 7), Ctns–/– (n ¼ 7), Gal-3–/– (n ¼ 3), and Ctns–/– Gal-3–/– mice (n ¼ 10). P values were determined using 1-way analysis
of variance followed by Tukey’s test. *P < 0.05. (b) Lysates of 293T cells transfected with Gal-3–green fluorescent protein (GFP) and MCP-1–
DsRed or Gal-3–GFP and CTNS-DsRed (control) were immunoprecipitated with anti-GFP antibody and co-immunoprecipitated proteins were
analyzed by Western blotting. (c) The same lysates were treated or not treated with 5 mM of N-Acetyl-D-lactosamine, a potent inhibitor of
Gal-3 carbohydrate interactions. Lysates were then immunoprecipitated with anti-GFP antibody and co-immunoprecipitated proteins were
then analyzed by Western blotting. (d) An enzyme-linked immunosorbent assay (ELISA) directed against human MCP-1 has been used to
determine MCP-1 expression in human serum samples from healthy donors (n ¼ 10) and cystinotic patients (n ¼ 19). P values were
determined using the unpaired 2-tailed Student t-test. ***P < 0.001. (e) Using an ELISA assay, Gal-3 expression was determined in human
serum samples from healthy donors (n ¼ 10) and cystinotic patients (n ¼ 17). P values were determined using the unpaired 2-tailed Student
t-test. NS, not significant. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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T Lobry et al.: Role of galectin-3 in cystinosis ba s i c re sea r chThis novel pathway of cystinosin-dependent Gal-3 lyso-
somal localization and degradation is supported in vivo as
Ctns-deficient mice exhibit overexpression of Gal-3 within the
kidney. Moreover, whereas increased Gal-3 mRNA was
limited in Ctns–/– kidneys compared with another model of
CKD, a large quantity of Gal-3 protein was detected only in
Ctns–/– kidneys. These data strongly support the conclusion
that cystinosin is involved in the degradation of Gal-3 protein,
which can control overexpression of Gal-3 mRNA in stress
conditions such as CKD.
Gal-3 has several biologic roles, including roles in acute
and chronic inflammation by attracting monocytes and
macrophages.37,38 In Ctns–/– mice, we observed heavy
mononuclear infiltrates mainly in the kidney as previously
described,11,39 which were characterized as monocytes/
macrophages. In contrast, kidneys from the double
knockout Ctns–/– Gal-3–/– mice exhibited very few mono-
cyte/macrophage infiltrates, strongly suggesting that Gal-3 is
involved in inflammation in the kidneys of Ctns–/– mice. In
the context of repetitive tissue injury, Gal-3 may trigger the
transition to chronic inflammation and fibrosis.34 Consis-
tent with these findings, our data demonstrate the
involvement of Gal-3 in the progression of the CKD in
cystinosis. Indeed, the double knockout Ctns–/– Gal-3–/–
mice exhibited better kidney function and structure
compared with Ctns–/– mice. Similarly, Gal-3–deficient mice
exhibit less renal fibrosis in the kidney compared with WT
mice after unilateral ureteric obstruction,40 and Gal-3
knockout mice subjected to ischemia-reperfusion injury
had a better renal function compared with WT mice sub-
jected to ischemia-reperfusion injury.41
Although a correlation between levels of Gal-3 in plasma
and the development of CKD was found,42 no difference of
Gal-3 expression was observed in the serum of mice and
humans affected by cystinosis and healthy control subjects. By
measuring different cytokine levels in the serum, we found a
significant increase of MCP-1 in Ctns–/– mice, whereas Ctns–/–
Gal-3–/– mice had levels comparable with those of WT mice.
MCP-1 is a cytokine that can be released in the serum and
forms a gradient to attract monocytes and macrophages to the
site of injury.35 The increase of MCP-1 in the sera of Ctns–/–
mice compared with Ctns–/– Gal-3–/– mice was independent
of cystine accumulation because kidney cystine content was
similar in both genotypes. Furthermore, despite cysteamine
treatment that allowed the exit of cystine out of the lyso-
somes, MCP-1 was found to be significantly increased in the
sera of patients with cystinosis compared with healthy donors.
These data strongly suggest that the absence of cystinosin,
rather than cystine accumulation, is responsible for MCP-1
increase in serum. In addition, we showed a direct interac-
tion between Gal-3 and MCP-1, which was recently suggested
by Gordon-Alonso et al.43 but was not studied any further.
The mechanism of Gal-3–mediated MCP-1 activation was not
studied here. A hypothesis is the presence of a signal peptide
in the human MCP-1, which can be cleaved to enhance its
secretion.44 Moreover, plasmin can cleave the C-terminus ofKidney International (2019) 96, 350–362MCP-1, which increases its chemoattractant potency.45 In
addition, correlating with our data, inhibition of MCP-1 in a
mouse model of diabetic nephropathy prevented renal
macrophage infiltration and improved renal function.46,47 In
cystinosis, our data strongly suggest that the absence of cys-
tinosin leads to the increase of Gal-3, which activates MCP-1
blood mobilization, enhancing renal inflammation and the
progression of chronic kidney disease.
These findings open new perspectives in potential thera-
peutic targets that could limit or delay kidney degeneration in
patients with cystinosis. Indeed, nonsteroidal antiin-
flammatory drugs such as aspirin and indomethacin have
been found to inhibit Gal-3 expression by inhibiting its
transcription.48 Indomethacin is actually used to regulate
polyuria and polydipsia in cystinosis,49 and a recent study of
307 European patients with cystinosis showed an improved
renal outcome in patients treated with indomethacin.50 In
light of our study, the use of indomethacin or nonsteroidal
antiinflammatory drugs for cystinosis patients may be
reconsidered.METHODS
Animal experiments
The C57BL/6 Ctns–/– mice were provided by Dr. Antignac (Inserm
U1163, Paris, France). C57BL/6 galectin-3 null (Gal-3–/–) mice were
provided by Dr. Fu-Tong Liu (University of California, Davis) and
Dr. Jerrold M. Olefsky (University of California, San Diego). The
breeding strategy to generate WT, Ctns–/–, Gal-3–/–, Ctns–/– and Gal-
3–/– mice is described in Supplementary Methods.
Cell lines
MEFs were generated from newborn skin biopsies of WTand Ctns–/–
mice. MEF, 293T, and MDCK type II cell lines (ATCC, Manassas,
VA) were grown in Dulbecco’s modified Eagle medium containing
10% fetal calf serum or fetal bovine serum, 100 units/ml penicillin,
0.1 mg/ml streptomycin, and 2 mM L-glutamine.
Co-immunoprecipitation and mass spectrometry analysis
To study protein-protein interactions, MDCK cells were transduced
using the lentiviral pRRL.SIN.cPPT.PGK/WPRE vector backbone
to stably express cystinosin-GFP.51 Co-immunoprecipitation was
performed as described in Supplementary Methods. Co-
immunoprecipitated proteins were resolved by sodium
dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE)
and analyzed by mass spectrometry, LTQ Orbitrap as already
described.19
293T cells expressing Gal-3–GFP and MCP-1–DsRed or Gal-3–
GFP and CTNS-DsRed were used for co-immunoprecipitation as
described in Supplementary Methods. Co-immunoprecipitated
proteins were resolved by SDS-PAGE, and Gal-3–binding MCP-1
was detected using anti-DsRed antibody (Clontech Laboratories,
Mountain View, CA).
Subcellular Fractionation
Eight livers were obtained from C57BL/6 mice and prepared as
described previously.52 Conditions of the gradient were essentially
the same as described in the original publication,52 except that
Nycodenz was used instead of metrizamide.359
bas i c re sea r ch T Lobry et al.: Role of galectin-3 in cystinosisGal-3–inhibitor and proteinase K treatments
Lysates from cystinosin-GFP MDCK cells and 293T expressing Gal-
3–GFP and CTNS-DsRed or Gal-3–GFP and MCP-1–DsRed were
incubated with or without 5 mM thiodigalactoside or 5 mM of N-
Acetyl-D-Lactosamine, respectively, 2 inhibitors of Gal-3 CRD. After
30 minutes of incubation at 4 C with constant shaking, lysates were
incubated with 50 ml anti-GFP microbeads and immunoprecipita-
tion was performed as mentioned previously. Precipitated proteins
were resolved by SDS-PAGE on 10% gel.
Lysates from cystinosin-GFP MDCK cells and mouse liver
lysosome-enriched fractions were incubated with or without 2%
Triton X-100 for 10 minutes at 4 C and then incubated 30 minutes
with or without 2.5 mg/ml and 25 mg/ml proteinase K, respectively.
After enzyme inactivation with 1 mM phenylmethylsulfonyl fluoride
for 5 minutes at 4 C, proteins were resolved by SDS-PAGE on 10%
gel.
Immunofluorescence analysis
Fixed MDCK cells were incubated with anti–Lamp-2 (OriGene
Technologies, Rockville, MD) and anti–Gal-3 antibody (Cedarlane
Laboratories, Burlington, Ontario, Canada) 2 hours at room tem-
perature, followed by Alexa Fluor 555 secondary antibody (Invi-
trogen, Carlsbad, CA) for 1 hour at room temperature. Confocal
images were taken using a Zeiss LSM 700 microscope (Carl Zeiss
Microscopy, Jena, Germany).
293T cells transiently expressing Gal-3–GFP alone, Gal-3–GFP,
and DsRed or Gal-3–GFP and cystinosin-DsRed were cultured on a
coverslip before being mounted on a slide. Cells were imaged using a
Keyence BZ-X700 instrument (Keyence Corp., Osaka, Japan).
Fixed kidney sections were incubated overnight at 4 C with
anti-CD68 (BioLegend, San Diego, CA) or anti–Gal-3 antibody
(BioLegend), followed by Alexa Fluor 488 secondary antibody
(Invitrogen), 1 hour at room temperature. Images were acquired
using a Keyence BZ-X700 instrument. Quantification of CD68
expression is described in Supplementary Methods.
MEFs expressing Gal-3–GFP were stained using anti-Hsc70
antibody (Enzo Life Sciences, Farmingdale, NY) and imaged as
described previously.53
Total internal reflection fluorescence microscopy
WT and Ctns–/– MEF expressing Gal-3–GFP and CTNS-DsRed were
seeded on a 4-chamber 35- mm borosilicate bottom dish (Cellvis,
Mountain View, CA). After 2 days in culture, MEFs were analyzed by
total internal reflection fluorescence microscopy as described pre-
viously54 and in Supplementary Methods. Images were analyzed
using ImageJ software.
Gal-3 expression analysis
293T cells expressing Gal-3–GFP, Gal-3–GFP and DsRed, or Gal-3–
GFP and CTNS-DsRed and explanted kidneys were lysed in radio-
immunoprecipitation assay buffer containing a proteinase inhibitor
cocktail. Proteins were separated on a 4% to 15% gel and revealed
using anti–Gal-3 (Abcam, Cambridge, UK) or anti–glyceraldehyde-
3-phosphate dehydrogenase (Cell Signaling Technology, Danvers,
MA) antibody.
Kidneys were homogenized in RLT buffer containing
b-mercaptoethanol using Precellys 24 (Bertin Instruments,
Montigny-le-Bretonneux, France). RNA was isolated and Gal-3–
specific droplet digital polymerase chain reaction was performed as
described in Supplementary Methods. Gal-3 transcript expression
was expressed as a ratio compared with the endogenous control 18S.360An enzyme-linked immunosorbent assay (Abcam) was used to
detect the Gal-3 level in mice and human sera, according to man-
ufacturer’s instructions.
Renal function
Serum and urine phosphate, serum creatinine, and urea levels were
estimated using the QuantiChrom Phosphate Assay Kit, Quanti-
Chrom Creatinine Kit, and QuantiChrom Urea Assay Kit (Bioassay
Systems, Hayward, CA). Protein levels in urine were measured using
the Pierce BCA Protein Assay Kit (Rockford, IL).
Histology
At time the mice were killed, kidneys were collected, fixed in
formalin, and embedded in paraffin. Sections stained with hema-
toxylin and eosin were reviewed in a blinded fashion by Dr. Marie-
Claire Gubler as described in the Supplementary Methods.
Cystine content measurement
Tissue cystine measurement was performed by mass spectrometry
(LC-ESI-MS/MS) as described previously.39
Standard nephrectomy and sham operation
Mice CKD was induced by the standard subtotal 2-stage nephrec-
tomy operation as described previously.55,56 The sham group of mice
underwent the same procedure but without cutting any kidney
tissue.
Cytokine level in serum
To measure cytokine levels in mouse serum, a mouse inflammation
kit cytometric bead array (BD Biosciences, San Jose, CA) was per-
formed according to the manufacturer’s instructions. MCP-1 con-
centration in human serum was determined using an enzyme-linked
immunosorbent assay directed against MCP-1 (Abcam, Cambridge,
UK) according to the manufacturer’s instructions.
Statistical analysis
Values are expressed as mean  SEM. The significance of the results
was assessed by unpaired 2-tailed t-test or unpaired 2-tailed t-test
with Welch’s correction. Group comparisons of 3 conditions or more
were made with parametric analyses of variance, followed by Tukey’s
multiple comparisons test for pairwise comparisons. Histologic
scores were compared using the Mann-Whitney test. Analyses were
performed using Prism 6 software (GraphPad, San Diego, CA). A P
value less than 0.05 was considered significant.
Study approval
Mice experiments were conducted in compliance with Institutional
Animal Use Committee protocols. Use of human tissue in this study
was approved by the University of California, San Diego, Human
Research Protections Program.
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SUPPLEMENTARY MATERIAL
Supplementary Information About Methods.
Figure S1. Galectin-3 (Gal-3) is localized in the lysosomes of wild-type
Madin-Darby canine kidney (MDCK) cells. Lysate of wild-type MDCK
cells was treated or not treated with proteinase K in the presence or
absence of Triton X-100 that permeabilizes lysosomal membranes.
Samples were then loaded on sodium dodecylsulfate–polyacrylamide
gel electrophoresis and revealed with anti–gal-3 or anti–cathepsin-D
(an intralysosomal hydrolase) antibody.
Figure S2. Kidney structures are preserved in 12-month-old Ctns–/–
Galectin-3 (Gal-3)–/– mice compared with Ctns–/– mice. Representative
histologic pictures of kidney sections from 12-month-old Ctns–/– and
Ctns–/– Gal-3–/– mice were stained with hematoxylin and eosin. More
abundant cortical injury and mononuclear infiltrates (arrows) were
observed in Ctns–/– kidneys than in Ctns–/– Gal-3–/– kidneys.
Figure S3. Infiltration of CD68þ, major histocompatibility class (MHC)
class IIþ and CD45þ macrophages in kidneys of 9-month-old Ctns–/–
mice. Representative confocal microscopy pictures of immunostain-
ing of cellular infiltrates in 9-month-old Ctns–/– kidneys are provided.
The cells are macrophages that co-express CD68 (red) and CD45
(green; upper panel) or CD68 (red) and MHC class II (green; lower
panel). Bar ¼ 20 mm.
Figure S4. Galectin- 3 (Gal-3) is expressed by CD68þ macrophages
and in renal cells in Ctns–/– kidneys. Representative confocal
microscopy pictures of immunostaining of kidney sections from 9-
month-old Ctns–/– mice with anti–Gal-3 antibody (green) and anti-
CD68 antibody (red) shows partial co-localization of both proteins
(arrows; upper panel), suggesting that CD68þ macrophages express
Gal-3. In addition, kidney cells also can express Gal-3 (arrowheads;
lower panel). Bar ¼ 100 mm.
Movie S1. Visualization of the dynamics of vesicles carrying Galectin-
3–GFP and cystinosin-DsRed in Ctns–/– fibroblasts using total internal
reflection fluorescence microscopy.
Movie S2. Visualization of the dynamics of vesicles carrying Galectin-
3–GFP and cystinosin-DsRed in Ctns–/– fibroblasts using total internal
reflection fluorescence microscopy.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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